FIZE Medical develops the FIZE kUO®, a commercially available system that provides real-time digital monitoring to support precision fluid management for critically ill patients. The company positions its platform as enabling earlier intervention through continuous monitoring and AI-driven data insights. FIZE is pursuing expanded commercial adoption in the U.S., Europe and Japan while also investing in next-generation AI capabilities. It plans to increase clinical validation studies within leading hospitals to build evidence for its approach. Financially, the company recently increased its Series A financing to $36 million following a $6 million warrant exercise by existing investors. FIZE emphasizes ongoing innovation and clinical evidence generation as central to its growth strategy.

Total raised

$25M

Funding rounds

3

Latest round

Equity

Latest activity

Mar 2026